Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of nitrendipine cas 39562-70-4 in China. Welcome to wholesale bulk high quality nitrendipine cas 39562-70-4 for sale here from our factory. Good service and reasonable price are available.
Nitrendipine is a classic dihydropyridine calcium channel blocker.Nitrendipine is a classic dihydropyridine calcium channel blocker. It effectively inhibits the influx of extracellular calcium ions by highly selectively antagonizing the L-type calcium channels in vascular smooth muscle. This leads to the dilation of peripheral blood vessels and coronary arteries. It effectively inhibits the influx of extracellular calcium ions by highly selectively antagonizing the L-type calcium channels in vascular smooth muscle. It significantly reduces peripheral resistance and produces a stable antihypertensive effect. This leads to the dilation of peripheral blood vessels and coronary arteries. This drug has a milestone significance in the development of cardiovascular pharmacology, not only laying the foundation for the subsequent research and development of long-acting calcium antagonists, but also deepening people's understanding of selective vasodilatory treatment.
|
|
|
|
Chemical Formula |
C18H20N2O6 |
| Exact Mass | 360.13 |
| Molecular Weight | 360.37 |
| m/z | 360.13 (100.0%), 361.14 (19.5%), 362.14 (1.8%), 362.14 (1.2%) |
| Elemental Analysis | C, 59.99; H, 5.59; N, 7.77; O, 26.64 |
Nitrendipine, also known as Nifedipine, is a second-generation calcium channel blocker with a chemical formula of C18H20N2O6. It is an ideal drug for the treatment of hypertension, possessing significant and lasting hypotensive and vasoconstrictive effects.
Pharmaceutical Applications
Treatment of Hypertension
- Primarily used for the treatment of various types of hypertension, including primary and secondary mild to moderate hypertension. It selectively acts on vascular smooth muscle to lower blood pressure.
- In clinical practice, it has been found that it can effectively reduce blood pressure and maintain it within a normal range, thereby reducing the risk of cardiovascular and cerebrovascular diseases.
Use in Cardiovascular Diseases
- Besides hypertension, it can also be used in the treatment of coronary heart disease and congestive heart failure.
- By inhibiting calcium influx into myocardial cells, it reduces myocardial oxygen consumption and protects ischemic myocardium.
Mechanism of Action
Selective Inhibition of Calcium Influx
Selectively inhibits the influx of calcium ions into vascular smooth muscle cells. By blocking the calcium channels on the cell membrane, it reduces the intracellular calcium concentration, leading to relaxation of vascular smooth muscle and dilation of blood vessels.
Decreased Peripheral Vascular Resistance
The dilation of blood vessels, especially those in the periphery, results in a decrease in peripheral vascular resistance. This decrease in resistance facilitates easier blood flow and subsequently lowers blood pressure.
Cardioprotective Effects
In addition to its hypotensive effects, it also has cardioprotective properties. It reduces myocardial oxygen consumption by dilating coronary arteries and coronary arterioles, thereby increasing myocardial oxygen supply in patients with coronary artery spasm. This can be beneficial in the treatment of ischemic heart disease.
Clinical Applications
Nitrendipine is primarily used in the treatment of hypertension, particularly mild to moderate hypertension, whether primary or secondary. Its significant and sustained hypotensive and vasoconstrictive effects make it an ideal choice for managing blood pressure. Additionally, it can also be used in the treatment of coronary heart disease and congestive heart failure, due to its ability to reduce myocardial oxygen consumption and increase myocardial oxygen supply.
Dosage and Administration
The usual dosage for hypertension is initiated at 10 mg once daily, which can be adjusted upwards to 20 mg twice daily based on individual patient response. It is administered orally and should be taken as prescribed by a healthcare provider.
Adverse Reactions
While it is generally well-tolerated, some patients may experience adverse reactions such as headache, facial flushing, dizziness, nausea, ankle swelling, and mild reflex tachycardia. Rarely, more severe adverse effects such as hypotension, allergic reactions, and acute urinary retention may occur. Therefore, it is important to monitor patients closely during treatment and adjust the dosage accordingly.
Precautions
- Patients with liver dysfunction may have increased blood drug concentrations, and those with renal insufficiency have minimal impact on pharmacokinetics. Therefore, caution should be exercised in these patients.
- Regular blood pressure monitoring is required during treatment, especially during initial dose adjustment or when increasing the dosage, especially when combined with β-blockers.
- Patients with severe coronary artery stenosis may have an increased incidence of angina pectoris or myocardial infarction during treatment or dose increase. Therefore, regular electrocardiographic monitoring is necessary.
combination use
- Mechanism: β-blockers can inhibit the release of renin, block the renin-angiotensin-aldosterone system's regulation of blood pressure, and reduce blood pressure. When combined with it, they can enhance the antihypertensive effect and may reduce tachycardia.
- Example Drugs: Propranolol, Atenolol, etc.
- Precautions: Individual patients may experience induced or exacerbated hypotension, heart failure, and angina pectoris.
- Mechanism: ACEIs can reduce blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, thereby dilating blood vessels and reducing peripheral vascular resistance. The combination can lead to enhanced antihypertensive effects with good tolerability.
- Example Drugs: Captopril, Enalapril, etc.
- Advantages: The combination can not only lower blood pressure but also reduce the load on the heart, reverse left ventricular hypertrophy caused by hypertension, and inhibit "structural remodeling" of vascular smooth muscle.
- Mechanism: Diuretics reduce blood pressure by decreasing blood volume and cardiac output through natriuresis and diuresis. The combination can avoid hypokalemia caused by diuretics.
- Example Drugs: Hydrochlorothiazide, etc.
- Advantages: Can inhibit the release of aldosterone and thus does not cause hypokalemia.
- Mechanism: Cimetidine can mediate the inhibition of hepatic cytochrome P450 enzymes, altering the first-pass effect.
- Precautions: When combining with Cimetidine, dose adjustments may be necessary.
- When combining with other drugs, it is essential to monitor blood pressure closely and adjust the dosage according to the patient's response.
- Patients with hepatic or renal impairment may require dose adjustments due to changes in drug metabolism and excretion.
- Potential drug interactions should be considered, and appropriate adjustments should be made to avoid adverse reactions.
One of the advantages of nitrendipine lies in its minimal impact on heart rate and cardiac contractility, unlike some other antihypertensive medications. However, as with any medication, it carries potential side effects such as headache, dizziness, flushing, ankle swelling, and, in rare instances, palpitations and hypotension. Its use should be carefully monitored, especially in patients with impaired liver function or those concurrently taking other medications that may interact with it.
Nitrendipine, as a dihydropyridine calcium ion antagonist, has been widely used in the treatment of cardiovascular and cerebrovascular diseases such as hypertension due to its unique cardiovascular pharmacological effects since its inception. With the intensification of global population aging and the increasing awareness of health, the demand for therapeutic drugs for cardiovascular and cerebrovascular diseases continues to grow, providing broad development space for cardiovascular drugs. The following is a detailed explanation of its development prospects:
Market demand analysis
Population aging drives market demand growth
With the increasing aging of the global population, the proportion of the elderly population is increasing year by year, and the incidence rate of cardiovascular and cerebrovascular diseases is also increasing. As one of the main therapeutic drugs for cardiovascular and cerebrovascular diseases, its market demand will continue to grow. Especially in developing countries such as China, with the improvement of medical standards and the refinement of medical insurance policies, the elderly population's ability to pay for cardiovascular and cerebrovascular disease treatment drugs has increased, further driving the market demand for such cardiovascular drugs.
Enhancing awareness of chronic disease management
In recent years, with the increasing awareness of health, chronic disease management has gradually become the focus of people's attention. Hypertension, as one of the main risk factors for cardiovascular and cerebrovascular diseases, is highly valued for its prevention and treatment. As one of the effective drugs for treating hypertension, its market demand will continue to grow with the increasing awareness of chronic disease management.
Emerging markets have enormous potential
In emerging market countries, such as India and Brazil, with the rapid development of economy and the improvement of medical treatment, the incidence rate and mortality of cardiovascular and cerebrovascular diseases are increasing year by year. These countries have a huge demand for drugs for the treatment of cardiovascular and cerebrovascular diseases, providing a broad market space for such cardiovascular drugs.
Technological progress and product innovation
Improvement of drug delivery system
In order to improve its bioavailability and patient compliance, the improvement of drug delivery systems has become a current research hotspot. For example, novel drug delivery systems such as self microemulsifying drug delivery systems (SEDD) and solid dispersions can significantly improve the solubility and dissolution of the compound, thereby enhancing its bioavailability. In addition, new forms of formulations such as sustained-release and transdermal patches are constantly being explored to meet the treatment needs of different patients.
Optimization of drug combination therapy plan
The treatment of cardiovascular and cerebrovascular diseases often requires a combination therapy of multiple drugs. By optimizing its combination therapy with other drugs, the therapeutic effect can be improved and adverse reactions can be reduced. For example, combining this compound with diuretics, ACE inhibitors, or ARBs can more effectively lower blood pressure and reduce the occurrence of cardiovascular and cerebrovascular events.
Developing personalized treatment plans
With the development of precision medicine, the formulation of personalized treatment plans has become an important trend in the future treatment of cardiovascular and cerebrovascular diseases. By using genetic testing, biomarker monitoring, and other methods, more precise personalized treatment plans can be provided to patients, thereby improving treatment effectiveness and patient quality of life.
Analysis of Competitive Landscape
Intense market competition
As a veteran in the cardiovascular disease treatment drug market, it faces fierce competition from new drugs and other similar drugs. In order to maintain their market position, companies need to continuously invest in research and development, launch new products or improve existing products to meet the treatment needs of patients.
Patent expiration and competition with generic drugs
With the expiration of the original drug patent, generic drug companies have entered the market one after another, intensifying market competition. Generic drugs, with their low prices and similar therapeutic effects, have had a huge impact on the original drug market. Therefore, original pharmaceutical companies need to strengthen intellectual property protection and explore new business models to cope with competition from generic drugs.
International Competition and Cooperation
With the acceleration of globalization, the international competition and cooperation of such cardiovascular drugs have become an inevitable trend. Enterprises need to strengthen their connections with the international market, understand the market demands and regulatory requirements of different countries and regions, in order to better expand into the international market. At the same time, through cooperation with internationally renowned enterprises, R&D resources can be shared, R&D costs can be reduced, and R&D efficiency can be improved.
Hot Tags: nitrendipine cas 39562-70-4, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Picene, 2 4 chlorophenyl 4 dibenzo b d furan 3 yl 6 phenyl 1 3 5 triazine, 2 3 9 9 dimethyl 9H fluoren 3 yl 1 1 3 1 terphenyl 3 yl 4 6 diphenyl 1 3 5 triazine, 2 1 1 biphenyl 4 yl 4 4 spiro fluorene 9 9 xanthen 2 yl phenyl benzo h quinazoline, 3 10 phenylanthracen 9 yl phenyl boronic acid, dibenzo b d furan 1 amine